The U.S. Food and Drug Administration has approved Perseris (risperidone) for the treatment of schizophrenia in adults. Perseris is a long-acting injectable medication that is given once a month by a healthcare provider. It contains the same active ingredient as the oral medication risperidone, which is an atypical antipsychotic. This new formulation offers an alternative for adults who may benefit from less frequent dosing.
Schizophrenia is a chronic mental health condition that affects how a person thinks, feels, and behaves. Treatment often involves daily medication, which can be challenging for some patients. Perseris provides a way to receive the medication through a monthly injection, which may help improve adherence to treatment.
The approval means that doctors now have another option for maintenance treatment in adults with schizophrenia. However, it is important to note that patients must first tolerate oral risperidone before starting Perseris. Supplementation with oral risperidone is not recommended while on Perseris.
If you or a loved one has schizophrenia, talk to your doctor about whether Perseris might be a suitable option. Do not stop or change your current treatment without medical guidance. This approval adds to the available choices but does not replace the need for personalized care.